Inclusion Criteria:  Voluntary participation and face to face signed informed consent; 18 -- 75 years old, gender unlimited; The histological diagnosis was esophageal squamous cell carcinoma, and the clinical staging was stage II-IVA (according to AJCC stage 8, pre-treatment clinical staging was: CT1N2-3M0, CT2-4BN0-3M0). Initial treatment patients receiving radical concurrent chemoradiotherapy; Immunotherapy with or without combination; The primary tumor can be evaluated; No distant metastasis; No serious abnormal function of blood system, heart, lung, liver and kidney or immune deficiency; Hemoglobin (Hb) ≥9 g/dL; White blood cell (WBC) ≥3×109/L; Neutrophils (ANC)≥1.5×109/L; Platelet (PT)≥100×109/L; Bilirubin < 1.5 times the upper limit of normal; Alanine aminotransferase (ALT) and alanine aminotransferase (AST) ≤2.5 times the upper limit of normal; Serum creatinine ≤1.5 times the upper limit of normal value; The willingness of men or women of reproductive age to use contraception in the trial; Physical condition score ECOG 0 ~ 2; The expected survival time was >3 months.  Exclusion Criteria:  Patients who lacked an evaluation of CT body composition within 15 days prior to treatment initiation; Patients with severe intestinal function damage or inability to tolerate intestinal nutrition; The digestive tract is severely obstructed, unable to take food orally and unable/unwilling to undergo nasogastric tube or percutaneous gastrostomy; Previous surgery, chemoradiotherapy or bio-targeted therapy for esophageal cancer; Previous history of malignant tumor.